Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
14 févr. 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 janv. 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio to Participate in Upcoming Investor Conferences
18 janv. 2023 17h30 HE
|
Gritstone bio
EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference
15 déc. 2022 16h31 HE
|
Gritstone bio
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 déc. 2022 16h30 HE
|
Gritstone bio
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)
13 déc. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 nov. 2022 07h30 HE
|
Gritstone bio
EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone to Participate in Upcoming Investor Conferences
17 nov. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022
10 nov. 2022 09h00 HE
|
Gritstone bio
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months...
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
03 nov. 2022 16h05 HE
|
Gritstone bio
-- Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform -- --...